FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab)…
News
CAR T-Cell Candidate bb2121 Shows Promise in Heavily Pre-treated Myeloma, Interim Data Show
The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces…
Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy
Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening…
Open Enrollment for Phase 1 Trial Testing CS1-CAR T-Cell Therapy for Hard-to-Treat Myeloma
A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang Bio’s investigational autologous (patient-derived)…
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma…
Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA
Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma…
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (…
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called…
Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing
A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide)…
